SoftMaxx AI sells no peptides and takes no vendor money.
No supporting study We found no study of a peptide sold for looks that measured facial attractiveness, facial proportions or the jaw. Growth-hormone therapy in children has measured facial ratios and jaw growth (reported as preliminary trends); several topical peptide trials measured facial wrinkles. We found no peptide sold for looks shown to change an adult jaw; in adults, jaw overgrowth is documented in acromegaly, a disease of excess growth hormone.[1][2][3][4]
The tier describes the evidence for any peptide's effect on the jaw; stronger evidence on this page concerns MK-677's side effects in older adults.
The verdict
In adults, jaw overgrowth is documented in acromegaly, a disease of excess growth hormone [4]. We found no study of a peptide product that measured jaw bone, jaw angle or jawline in healthy adults.
We found no study showing that a cream or injection changes the gonial angle, the corner of the jaw.
| Claim | What the evidence shows |
|---|---|
| MK-677 grows the jaw | No trial we found measured facial bones [6] |
| Growth hormone grows the jaw | In adults, documented in acromegaly, a disease [4]; in children, one 6-month study of therapy for growth disorders reported jaw growth as preliminary trends [1] |
| Follistatin builds jaw muscle | We found no study |
| GLP-1 drugs sharpen the jaw | Rapid weight loss on semaglutide can deplete facial volume and fat [7]; we found no facial trial |
| Peptide creams lift the jaw | No topical trial we found measured sagging |
Growth hormone: jaw growth is a disease sign
Growth hormone comes up because jaw overgrowth is documented in adults with acromegaly, a disease of excess growth hormone [4].
We found no study showing growth hormone at medical doses reshaping a healthy adult face. Distributing it as an age-reversal agent is illegal in the US [9].
- Expert review Jaw overgrowth occurs in about 22–24% of people with acromegaly, and a forward-jutting jaw in about 20–22%.[4]
- Expert review In a systematic review of trials in healthy older adults, growth hormone gave small body-composition changes and more soft-tissue swelling, joint pain, carpal tunnel syndrome and breast enlargement.[9]
- Human observational Facial growth changes with growth hormone therapy are reported in children and adolescents with growth disorders; the studies are observational and did not test adults.[10][1]
- Expert review A 2007 systematic review states that distributing growth hormone as an age-reversal agent is illegal in the US; a 2005 article addresses the clinical and legal issues of providing it, and PubMed lists no abstract for it.[9][11]
MK-677: swelling, not structure
MK-677 (ibutamoren) [5] is an oral drug that mimics the hormone ghrelin and raises growth hormone [6]. We found no FDA approval for it, and FDA lists ibutamoren mesylate in 503A Category 2, its significant-safety-risk list for compounding [12].
Its 2-year trial recorded mild leg swelling and higher blood sugar [6]. We found no MK-677 trial that measured the face.
Follistatin: no jaw data, unreliable vials
Follistatin is a myostatin-inhibiting protein; a 2019 paper reported no approved pharmaceutical formulations of it [13]. The 2026 WADA Prohibited List names follistatin under S4.3 (WADA 2026 List).
We found no study of follistatin and the jaw or face muscles. In a lab analysis of 17 black-market "follistatin 344" products, only 9 contained follistatin [13].
- Case report A case series of 11 bodybuilders linked high-dose follistatin-344 injections to fluid under the retina, with blurred vision.[14]
GLP-1 drugs: the face follows body fat
Semaglutide and tirzepatide are FDA-approved drugs [15]. Rapid weight loss on semaglutide can lead to depleted facial volume and fat [7]; we found no study of whether it makes the jaw edge more visible.
The same fast loss can also leave hollowing and loose skin, called "Ozempic face". Your prescriber decides whether one of these drugs fits you.
- Common belief
"Ozempic face" is a special effect of the drug
Expert review Commentaries tie "Ozempic face" to rapid weight loss that depletes facial volume and fat and leaves sagging skin. One asks whether it is a new drug effect or a natural result of rapid weight loss, and leaves that open.[7][8] - Expert review A facial plastic surgery review describes depleted facial volume and fat, wrinkles and sagging skin after rapid weight loss on semaglutide, and says dermal fillers, skin tightening techniques and surgery are used to restore facial volume and manage excess skin.[7]
What creams can do for a softer jawline
Loose skin along the jaw is a skin question, not a bone one. Here the honest answer is small.
Topical peptide trials measured fine lines and wrinkles over weeks [2][3]. None we found measured sagging or jaw definition. More detail is on peptides for skin tightening.
Side effects and risks
- Human RCT MK-677: fluid retention, higher fasting glucose, lower insulin sensitivity[6]
- Human RCT MK-677: heart-failure signal that stopped a trial early[5]
- Expert review Growth hormone in healthy older adults (pooled trials): soft-tissue swelling, joint pain, carpal tunnel syndrome, breast enlargement[9]
- Case report High-dose follistatin-344 injections: fluid under the retina with decreased vision (case series of 11 bodybuilders)[14]
- Expert review Rapid weight loss on semaglutide: facial volume loss, wrinkles and sagging skin[7][17][18]
Regulatory status (checked 2026-09-30)
- United States (FDA)We found no FDA-approved product containing ibutamoren (MK-677) in Drugs@FDA (searched 2026-10-01). (FDA:
Drugs@FDA search: ibutamoren — no approved product found
) FDA lists Ibutamoren mesylate (MK-677) in 503A Category 2, “Bulk Drug Substances that Raise Significant Safety Risks”, added 2023-09-29. (FDA:Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
; FDA:Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
) Somatropin is FDA-approved as Genotropin (prescription drug). (DailyMed:GENOTROPIN (somatropin) — FDA prescribing information
) Semaglutide is FDA-approved as Ozempic and Wegovy (prescription drugs). (DailyMed:OZEMPIC (semaglutide) injection — Prescribing Information
; DailyMed:WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets — Prescribing Information
) Tirzepatide is FDA-approved as Mounjaro and Zepbound (prescription drugs). (DailyMed:MOUNJARO (tirzepatide) injection — Prescribing Information
; DailyMed:ZEPBOUND (tirzepatide) injection — Prescribing Information
) - CanadaWe found no product containing ibutamoren (MK-677) in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada:
Health Canada Drug Product Database search: ibutamoren — no product found
) Ozempic and Wegovy (semaglutide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada:Health Canada Drug Product Database: OZEMPIC (semaglutide) — Drug Identification Numbers listed
; Health Canada:Health Canada Drug Product Database: WEGOVY (semaglutide) — Drug Identification Numbers listed
) Mounjaro and Zepbound (tirzepatide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada:Health Canada Drug Product Database: MOUNJARO (tirzepatide) — Drug Identification Numbers listed
; Health Canada document) - Sport (WADA)Ibutamoren (MK-677) is named on the 2026 WADA Prohibited List (S2.2.4). (WADA:
World Anti-Doping Code International Standard Prohibited List 2026
) Somatropin is named on the 2026 WADA Prohibited List (S2.2.3). (WADA:World Anti-Doping Code International Standard Prohibited List 2026
) Semaglutide is not on the 2026 WADA Prohibited List. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
) Tirzepatide is not on the 2026 WADA Prohibited List. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
)
Report a side effect
If something went wrong after using any product, tell a clinician and report it. Reports are how regulators find contaminated or mislabeled products.
- FDA MedWatch (United States)
- Canada Vigilance Program (Canada)
Common questions
Can HGH grow your jaw?
In adults, jaw overgrowth is documented in acromegaly, a disease of excess growth hormone: mandibular overgrowth is reported in 22–24% of patients. In children with growth disorders, a 6-month study linked growth hormone therapy to growth of the lower jaw, which its authors call preliminary trends. We found no study of medical doses reshaping a healthy adult face.[4][1]
Can MK-677 make you taller or grow your jaw?
No trial we found supports it, and none measured facial bones. Its 2-year trial recorded mild leg swelling and worse blood sugar instead.[6]
Can follistatin grow your jaw or face muscles?
We found no study. Black-market vials often contain no follistatin, and high-dose use has been linked to a retinal disorder.[13][14]
References
Every reference below was matched to its PubMed or DOI record (title checked) before publication. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.
Effects of growth hormone therapy on facial anthropometric features in children with growth disorders: a cohort study.
PubMed 42583639 DOITopical palmitoyl pentapeptide provides improvement in photoaged human facial skin.
PubMed 18492182 DOIThe anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.
PubMed 23417317 DOIOral Manifestations and Maxillo-Facial Features in the Acromegalic Patient: A Literature Review.
PubMed 35207363 DOIMK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
PubMed 21067829 DOIEffects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
PubMed 18981485 DOIImplications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
PubMed 37541662 DOINatural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon.
PubMed 38206146 DOISystematic review: the safety and efficacy of growth hormone in the healthy elderly.
PubMed 17227934 DOIGrowth hormone deficiency: craniofacial characteristics and changes after growth hormone therapy - a systematic review.
PubMed 42714814 DOIProvision or distribution of growth hormone for "antiaging": clinical and legal issues.
PubMed 16249424 DOIBulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
SourceDetection of black market follistatin 344.
PubMed 31758732 DOICentral serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series.
PubMed 32671599 DOIDangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
PubMed 42757290Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 40324552 DOIThe rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists.
PubMed 39098289 DOIFacial Remodeling Addressing Fat Loss and Skin Sagging With Poly- l -Lactic Acid SCA and Hyaluronic Acid Filler After Semaglutide-Associated Prescriptive Weight Loss.
PubMed 40277199 DOI